PathFinderTG® is a patented advanced testing platform for resolving “indeterminate, atypical, suspicious, equivocal and non-diagnostic specimen” diagnoses from the original pathology specimen.  PathFinderTG integrates the power of quantitative genetic mutational analysis with the intelligence of pathology to deliver unprecedented diagnostic accuracy when differentiating between:

• Reactive versus neoplastic lesions
• Grade of dysplasia
• Benign versus malignant lesions
• Metastatic, synchronous and recurrent tumors
• Biologically indolent versus aggressive tumors

We have developed the broadest panel of markers for mutational analysis.  PathFinderTG is clinically and analytically validated for the following organs:

• All tissue (metastatic, synchronous and recurrent tumor differentiation)
• Biliary ducts
• Brain
• Breast
• Colon
• Endometrium
• Esophagus
• Liver
• Lung
• Ovary
• Pancreas
• Urothelial (tissue only)

RedPath does significant work in differentiating the following conditions:

• Pancreatic Cyst Aspirates: Benign v. Malignant (even with pauci and acellular specimens)
• Pancreatic Solid Mass Aspirates: Benign v. Malignant
• Brain: Benign v. Malignant
• Brain: Biologic Aggressiveness of Tumor
• Brain: 1p/19q deletion for chemo/radiation responsiveness
• Brain: Temporal sequence of acquired DNA mutations
• Barrett's Esophagus v. Esopageal cancer
• Barrett's Esophagus: Rate of progression and potential reversibility in patients with large field Barrett's dysplasia
• Bile Duct Brushings indeterminate for cancer
• Schlerosing cholangitis acquired mutational progression
• GI Tract: reactive healing v. cancer formationin ulcers and related lesions
• GIST: Biologic aggressiveness
• GIST: Therapeutic responsiveness (including C-Kit and PDGFRA mutational analysis)
• IBD: Discriminate regeneration, inflammatory atypia v. true dysplasia
• IBD: Discriminate tubulovillous adenoma v. DALM
• Colon polyps: pseudoinvasion v. true invasion
• Colon polyps: differentiate serrated v. adenomatous polyps
• Colon polyps: MSI test for HNPCC on polyps and resected tissue
• Liver: Intrahepatic spread v. de novo cancer formation in multinodular HCC

There is no other test available that gives the depth of information provided by PathFinderTG.  Our broad panel of genetic markers, microdissection techniques and proprietary DNA amplification techniques provide UNIQUE information about each individual cancer.  The seven parameters and potentially hundreds of individual analyses that are the foundation for PathFinderTG results are not available from any other laboratory.  While some labs offer parts of the analysis found in PathFinderTG, the information derived may be out of the appropriate context to make it clinically useful at the individual patient level.

RedPath works with the most minute specimens to extract meaningful information from each specimen.  PathFinderTG can produce quantitative mutational results from the patient’s initial specimen(s) using histology slides, cytology slides, fluid aspirates and brush samples.

Physicians: To order a PathFinderTG analysis simply download and complete a requisition form.  For more information on the capabilities of PathFinderTG testing, please contact us at (800) 495-9885.